These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 21841505

  • 1. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
    Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquée L, De Vuyst P, Germonpré P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP.
    J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
    [Abstract] [Full Text] [Related]

  • 2. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
    Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Chest; 2012 Feb; 141(2):477-484. PubMed ID: 21737491
    [Abstract] [Full Text] [Related]

  • 3. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
    Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquée L, Nackaerts K, Germonpré P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP.
    J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 5. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.
    J Thorac Oncol; 2008 Aug 01; 3(8):851-7. PubMed ID: 18670302
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 7. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R.
    Int J Biol Markers; 2017 Mar 02; 32(1):e126-e131. PubMed ID: 27646775
    [Abstract] [Full Text] [Related]

  • 8. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M.
    Clin Chem Lab Med; 2010 Feb 02; 48(2):271-8. PubMed ID: 20131968
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
    Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ.
    J Clin Oncol; 2009 Jun 20; 27(18):3007-13. PubMed ID: 19364962
    [Abstract] [Full Text] [Related]

  • 10. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.
    J Thorac Oncol; 2011 Sep 20; 6(9):1587-93. PubMed ID: 21642872
    [Abstract] [Full Text] [Related]

  • 11. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
    Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK.
    Clin Cancer Res; 2011 Mar 01; 17(5):1181-9. PubMed ID: 21177406
    [Abstract] [Full Text] [Related]

  • 12. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
    Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, Bannon PG, McCaughan BC.
    J Thorac Cardiovasc Surg; 2009 Sep 01; 138(3):619-24. PubMed ID: 19698846
    [Abstract] [Full Text] [Related]

  • 13. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
    Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, Iwakami S, Yamazaki M, Toba M, Tobino K, Sugano K, Ichikawa M, Hagiwara Y, Takahashi K, Hino O.
    Anticancer Res; 2008 Sep 01; 28(6B):3933-6. PubMed ID: 19192652
    [Abstract] [Full Text] [Related]

  • 14. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
    Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M.
    Eur J Surg Oncol; 2018 Jun 01; 44(6):792-798. PubMed ID: 29503128
    [Abstract] [Full Text] [Related]

  • 15. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
    Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A.
    Am J Respir Crit Care Med; 2009 May 15; 179(10):950-4. PubMed ID: 19201924
    [Abstract] [Full Text] [Related]

  • 16. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I.
    J Thorac Cardiovasc Surg; 2015 Jun 15; 149(6):1539-46.e1. PubMed ID: 25840756
    [Abstract] [Full Text] [Related]

  • 17. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ.
    Ann Thorac Surg; 2017 Nov 15; 104(5):1679-1687. PubMed ID: 28964420
    [Abstract] [Full Text] [Related]

  • 18. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
    Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, van Meerbeeck JP, European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group.
    Eur Respir J; 2010 Dec 15; 36(6):1362-9. PubMed ID: 20525721
    [Abstract] [Full Text] [Related]

  • 19. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, Raiko I, Del Razo LM, Taeger D, Calderón-Aranda ES, Rihs HP, Acosta-Saavedra LC, Weber DG, Cabello-López A, Pesch B, Ochoa-Vázquez MD, Burek K, Torre-Bouscoulet L, Pérez-Padilla JR, García-Bazan EM, Brüning T, Johnen G, Aguilar-Madrid G.
    Lung; 2019 Oct 15; 197(5):641-649. PubMed ID: 31267149
    [Abstract] [Full Text] [Related]

  • 20. Complete response and long-term survival in malignant pleural mesothelioma: case report.
    Takanen S, Resuli B, Graziano V, Parisi A, Lisi R, Raffetto N, Tombolini V.
    Anticancer Res; 2012 Apr 15; 32(4):1485-7. PubMed ID: 22493390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.